Case Report: Effective management of adalimumab-induced acquired hemophilia A with the CyDRI protocol

• Váldodahkkit: Andrea Ceglédi (Dahkki), Árpád Bátai (Dahkki), János Dolgos (Dahkki), Mónika Fekete (Dahkki), László Gopcsa (Dahkki), Viktória Király (Dahkki), Gergely Lakatos (Dahkki), György Nagy (Dahkki), Zsuzsanna Szemlaky (Dahkki), Andrea Várkonyi (Dahkki), Beáta Vilimi (Dahkki), Gábor Mikala (Dahkki), Imre Bodó (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Frontiers Media S.A., 2024-05-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

IntroductionAcquired Hemophilia A (AHA) is a rare autoimmune disorder characterized by the emergence of inhibitors that specifically target coagulation Factor VIII, frequently resulting in severe bleeding episodes.MethodsWe conducted a retrospective analysis of the medical records of a 68-year-old m...